findmyKOL

Robert Negrin, MD

Enriched profile

Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy) · Stanford University

ORCIDNone on fileNPI↗
✓ Full profile
Region🇺🇸 Stanford, CA · West · United StatesSpecialtyHematologyFocusMyeloproliferative Disorders
Active KOLfindmyKOL type: EliteLatest publicationNone indexedOnline presenceNone verifiedPayments2021–2024NIH funding1997–2026Why? →

Robert Negrin is Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy) at Stanford University. ClinicalTrials.gov lists 6 registered studies with this person as an investigator.

Data verified 18 Oct 2026

Overview

Updated 18 Oct 2026

Robert Negrin, M.D., is Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy) at Stanford University. The public record shows 634 publications with 27,883 citations (h-index 85), centered on Myeloproliferative Disorders. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 6 companies, 10 NIH-funded awards (1997–2026).

  • Top research focus: Myeloproliferative Disorders
  • 6 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 6 companies

Generated from the cited public record · current as of 18 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Leukemia (AML/ALL/CML/CLL)3 trialsLymphoma2 trialsMultiple Myeloma1 trialMDS / MPN1 trialMyeloproliferative Disorders1 trialAcute Disease1 trialLymphoma, Non-Hodgkin1 trialHematologic Diseases1 trial

Research focus

OpenAlex concept fingerprint
Myeloproliferative Disorders

Drugs & molecules

across trials, industry payments and publications
Defiteliogeneric · DefibrotideClinical trials—Industry payments1Publications—Yescartageneric · Axicabtagene ciloleucelClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
Amgen Inc.Clinical trials—Industry payments15Stanford UniversityClinical trials5Industry payments—Coherus Biosciences Inc.Clinical trials—Industry payments2Takeda Pharmaceuticals U.S.A., Inc.Clinical trials—Industry payments2CellSight Technologies, Inc.Clinical trials1Industry payments—Jazz Pharmaceuticals Inc.Clinical trials—Industry payments1Kite Pharma, Inc.Clinical trials—Industry payments1ZOLL Medical CorporationClinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
85h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
6clinical trials

Investigator role on registered studies.

View trials ↓
6companies · 2021–2024

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
10NIH grants · 1997–2026

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 18 Oct 2026

Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 18 Oct 2026

6 companies reported payments to CMS in program years 2021–2024. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Anti-infectives

    35.8%
    Short-acting sulfonamides19.8%
    Sulfamethoxazole-Trimethoprim100%
    Part D<11 patients
    Azole Antifungal16%
    Fluconazole100%
    Part D<11 patients
  • Dermatology

    32.1%
    Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor32.1%
    Acyclovir100%
    Part D<11 patients
  • Metabolism & gastrointestinal

    18.5%
    Corticosteroid18.5%
    Prednisone100%
    Part D<11 patients
All 4 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B)100% facility · 0% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 18 Oct 2026

10 NIH research awards on record, funded 1997–2026 per NIH RePORTER. The latest:

Publications

None on file yet. We only list publications we can confidently match to this person. Why? →

Online presence

Updated 18 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Mentions by others

where others cite or feature them
  • Other

    aacr.org/governance/robert-s-negrin

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aacr.org ↗
  • Other

    isctglobal.org/telegrafthub/blogs/francheska-juliano/2026/01/12/leadership-spotlight-robert-negrin-md-isct-past-pr

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →isctglobal.org ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 18 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • President

    American Society of Hematology

    2026
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
  • Editor-in-Chief

    Blood Advances

    2017
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
  • verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
  • President

    American Society for Transplantation and Cellular Therapy

    2006
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →isctglobal.org ↗
  • Past President

    International Society of Cellular Therapy

    2002
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →isctglobal.org ↗
  • Member

    American Society of Hematology

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
  • Member

    International Society for Cellular Therapy

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
  • Member

    American College of Physicians

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
  • Member

    American Association for the Advancement of Science

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
  • Member

    Bio-X

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
  • Member

    Maternal & Child Health Research Institute (MCHRI)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗
  • Member

    Stanford Cancer Institute

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.stanford.edu ↗

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.